STAT

SEPTEMBER 12, 2024

The company also said that it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. The announcement was made ahead of a meeting being held by Moderna on Thursday to update investors on its research and development efforts. Continue to STAT+ to read the full story…

Drug Development 329

Drug Development Vaccines 329

European Pharmaceutical Review

SEPTEMBER 6, 2023

million by 2028, with a CAGR of 7.3 percent from 2023 to 2028. Between 2023 to 2028, the research suggested that a greater focus on drug development, growing requirement for spectroscopy via cloud-based platforms, alongside the industry’s need for precise and effective analytical methods, will drive the market.

Drug Development 98

Drug Development 98

STAT

JUNE 3, 2024

Kaiser, which is both a health insurance company and a network of providers, said it wants to add at least five to six more health systems by 2028. Geisinger’s 10 hospitals and 1,700 employed physicians are now officially part of the group, known as Risant Health. Those other organizations are still a mystery.

Hospitals 316

Hospitals Health Insurance Companies 316

pharmaphorum

JUNE 8, 2023

Standalone Sandoz eyes $3bn in new product sales by 2028 Phil.Taylor Thu, 08/06/2023 - 07:57 Bookmark this

96

96

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Vaccines 105

Vaccines Drug Development 105

European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. billion during 2028.

Vaccines 98

Vaccines Immunity Immunization 98

STAT

SEPTEMBER 28, 2023

The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians. Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives.

Hospitals 341

Hospitals 341

Pharmafile

MARCH 30, 2023

After receiving FDA approval in January 2023, Biogen/Eisai’s new Alzheimer’s disease Leqembi is expected to become a blockbuster, with a predicted $12.9bn predicted to be made in sales between 2023 and 2028. The drug is still awaiting approval in the EU and Japan, with these approvals potentially making it the top-selling Alzheimer’s drug.

83

83

STAT

OCTOBER 29, 2024

Beginning in 2028, Dana-Farber will end its long and nationally acclaimed adult oncology partnership with Brigham and Women’s Hospital. Instead, it will team up with Beth Israel Deaconess Medical Center to  open a new freestanding  300-bed, $1.68 billion cancer hospital in the Longwood Medical Area.

Hospitals 221

Hospitals 221

STAT

NOVEMBER 19, 2024

patent expires in 2028. For Merck, the new under-the-skin, or subcutaneous, formulation of Keytruda could represent a major way of holding on to a larger share of Keytruda’s $25 billion in annual sales than would otherwise occur when the medicine’s U.S. It is the best-selling medicine in the world.

Immunity 333

Immunity Immunization 333

STAT

JULY 29, 2024

Thomas Schinecker, chief executive of the pharmaceutical company, said its first obesity drugs would come to market “significantly faster than people are expecting,” potentially by 2028. The treatments, acquired in a $3.1 reduction in weight compared with a placebo after four weeks.

Pharmaceutical Companies 266

Pharmaceutical Companies Pharmaceutical Companies 266

STAT

JANUARY 25, 2023

The data is a setback for Merck, which has been working to expand use of Keytruda, which has powered its growth for years but will lose exclusivity in 2028. The drug was being tested in combination with androgen deprivation therapy and Xtandi in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

235

235

STAT

NOVEMBER 19, 2024

patent expires in 2028. For Merck, the new under-the-skin, or subcutaneous, formulation could represent a major way of holding on to a larger share of Keytruda’s $25 billion in annual sales than would otherwise occur when a U.S.

Biosimilars 290

Biosimilars Immunization Immunity Pharmaceutical Companies 290

BioPharma Dive

AUGUST 29, 2024

The trial setbacks for Merck’s best-selling drug, which faces patent expiration in 2028, are a blow to the company’s plans for further indication expansion.

111

111

PharmaTech

OCTOBER 8, 2024

According to the annual survey, four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which are expected to have 45% of all CMO capacity in Asia.

52

52

Pharmaceutical Technology

OCTOBER 25, 2024

A new vaccines drug substance facility and R&D pilot plant, completed by the end of 2028, will create over 200 new jobs.

Vaccines 98

Vaccines 98

BioPharma Dive

APRIL 20, 2023

With the court victory, the biotech giant could stave off a set of generic competitors for the top-selling drug until 2028.

105

105

Pharmaceutical Technology

DECEMBER 18, 2024

A new report identifies data content management as the primary driver of growth in the pharmaceuticals market.

59

59

STAT

NOVEMBER 14, 2024

The cancer immunotherapy Keytruda, which is Merck’s most important product and the best-selling drug in the world with $23 billion in annual sales, is set to lose patent protection and face competition from generic drugmakers as early as 2028.

253

253

Outsourcing Pharma

DECEMBER 3, 2024

Discover how a strategic acquisition in pharma packaging is set to drive growth as the market aims to double by 2028

Packaging 75

Packaging 75

European Pharmaceutical Review

MARCH 20, 2024

million by 2028. percent between 2022-2028, the research found. Based on the research, the US LIMS market is predicted to value $1 billion by 2028. According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 The market is growing at a CAGR of 10.16

98

98

European Pharmaceutical Review

DECEMBER 4, 2023

billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. Moreover, the non-toxic nature of organic chemicals is expected to drive the organic chemicals sectors, ultimately boosting the pharmaceutical excipient market in the forecast period (2023 to 2028).

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

BioPharma Dive

JANUARY 29, 2024

An under-the-skin Opdivo shot produced similar results to an intravenous formulation in kidney cancer, giving Bristol Myers a chance at sustaining sales past a key patent expiration in 2028.

75

75

Pharmacy Times

JANUARY 22, 2024

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

58

58

Express Pharma

JANUARY 31, 2024

GlobalData’s Respiratory Syncytial Virus (RSV) Forecast in Asia-Pacific Markets to 2028 reveals that Urban China will lead the Asia-Pacific (five growth markets*) market for RSV in 2028, accounting for 34.8 Hence, the approval addresses an urgent need for novel prophylactic treatment options for the pediatric population in China.”

103

103

STAT

SEPTEMBER 12, 2024

In a press release issued ahead of an investor meeting today, the company also said it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. … Moderna plans to cut its annual spending on research and development by 23%, or $1.1

Packaging 146

Packaging Diabetes Vaccines 146

Pharmaceutical Commerce

SEPTEMBER 25, 2023

This would signify an 8.3% CAGR over the next five years.

52

52

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

52

52

Express Pharma

NOVEMBER 28, 2024

The project will be implemented from November 2024 to April 2028, focusing on the following goals: Developing a state-wide framework for Antimicrobial Stewardship (AMS) and IPC. A 2021 ICMR study reported AMR-related fatality rates of 38.1 per cent in bloodstream infections and 27.9

Hospitals 105

Hospitals 105

Pharmaceutical Commerce

JANUARY 18, 2024

The predicted value is largely driven by manufacturers' prioritization of brand protection.

52

52

Pharmaceutical Technology

JANUARY 15, 2024

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.

59

59

The Pharmacist

JUNE 30, 2023

Training places for pharmacists will be expanded by almost a third (29%) by 2028/29, NHS England has announced today within its new workforce plan. And the ambition is to increase training places for the profession by nearly 50% – to around 5,000 places per year – by 2031/32, it said.

75

75

pharmaphorum

APRIL 20, 2021

billion by 2028. billion in sales in 2028. Analyst Philippa Salter of GlobalData recently predicted that Kesimpta’s convenience will make it a sought-after option for RMS patients, driving global sales to $3.3 While it requires a clinic visit, Ocrevus only has to be administered twice a year.

Hospitals 111

Hospitals Documentation 111

pharmaphorum

APRIL 29, 2022

Meanwhile, rapid diagnostics has been identified as the biggest factor in cancer survival rates in the NHS Long Term Plan, which lays out a target to increase the proportion of cancers diagnosed at stages 1 and 2 from half to three quarters by 2028.

Hospitals 145

Hospitals 145

Pharmaceutical Technology

JANUARY 9, 2024

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

52

52

PharmaTech

OCTOBER 11, 2024

The draft joint network strategy for the EU until 2028 will be open for public consultation until Nov. 30, 2024.

52

52

Express Pharma

APRIL 25, 2024

As Lynparza’s patent protection in the US market will expire in 2028, there is an anticipated downshift in sales post-patent expiry through generic erosion.

Chemotherapy 116

Chemotherapy 116